Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes
- PMID: 12620642
- DOI: 10.1016/s0165-5728(03)00006-7
Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes
Abstract
In multiple sclerosis (MS), matrix metalloproteinase (MMP) activity in tissues is the result of a balance between MMPs and their tissue inhibitors (TIMPs). MMP-9 predominates in acute MS lesions and is inhibited by TIMP-1, while MMP-2 may participate in the remodeling of the extracellular matrix (ECM) such as in chronic disease and is inhibited by TIMP-2. These differences may be reflected in serum and cerebrospinal fluid (CSF). We have tried to characterize MMP-2 and MMP-9 activities, in relation to their respective TIMPs, 2 and 1, as a factor of different types of the disease, as this information was not previously clearly stated. We found the MMP-2/TIMP-2 ratio in serum to show higher values in secondary progressive (SP, p=0.02) and primary progressive (PP, p=0.01) MS than short disease duration (SDD) relapsing-remitting (RR) MS, but not different from the healthy control (HC) group. Whereas the MMP-9/TIMP-1 ratio in serum showed higher (p=0.04) values in SDD RR MS than PP but also in active patients, evaluated either clinically (p=0.006) or from the magnetic resonance imaging (MRI, p<0.05), compared to inactive disease. CSF MMP to TIMP ratios did not differ between MS subtypes, suggesting systemic rather CNS-restricted changes. These results show that an increase in MMP-2/TIMP-2 ratio marks chronic progression in MS, but it is as high as in HC, and also confirm that high MMP-9 activity characterizes short duration relapsing and active forms of the disease.
Similar articles
-
Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment.Mult Scler. 2005 Aug;11(4):441-6. doi: 10.1191/1352458505ms1193oa. Mult Scler. 2005. PMID: 16042227 Clinical Trial.
-
Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis.Mult Scler. 2006 Jun;12(3):294-301. doi: 10.1191/135248506ms1274oa. Mult Scler. 2006. PMID: 16764342
-
Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.Eur J Neurol. 2010 Feb;17(2):226-31. doi: 10.1111/j.1468-1331.2009.02775.x. Epub 2009 Oct 1. Eur J Neurol. 2010. PMID: 19796283
-
IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS.Neurology. 2003 Jan 14;60(1):52-7. doi: 10.1212/wnl.60.1.52. Neurology. 2003. PMID: 12525717 Clinical Trial.
-
Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis.Neurology. 1999 Oct 22;53(7):1397-401. doi: 10.1212/wnl.53.7.1397. Neurology. 1999. PMID: 10534241
Cited by
-
Resistance training modifies of serum levels of matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases in multiple sclerosis women - a randomized controlled trail.BMC Neurosci. 2024 Mar 4;25(1):13. doi: 10.1186/s12868-024-00856-1. BMC Neurosci. 2024. PMID: 38438999 Free PMC article. Clinical Trial.
-
Astrocytic TIMP-1 regulates production of Anastellin, an inhibitor of oligodendrocyte differentiation and FTY720 responses.Proc Natl Acad Sci U S A. 2024 Jan 30;121(5):e2306816121. doi: 10.1073/pnas.2306816121. Epub 2024 Jan 24. Proc Natl Acad Sci U S A. 2024. PMID: 38266047 Free PMC article.
-
Arachidonic acid-derived lipid mediators in multiple sclerosis pathogenesis: fueling or dampening disease progression?J Neuroinflammation. 2024 Jan 17;21(1):21. doi: 10.1186/s12974-023-02981-w. J Neuroinflammation. 2024. PMID: 38233951 Free PMC article. Review.
-
Effect of Whole-Body Cryotherapy on Oxidant-Antioxidant Imbalance in Women with Multiple Sclerosis.J Clin Med. 2023 Sep 13;12(18):5958. doi: 10.3390/jcm12185958. J Clin Med. 2023. PMID: 37762899 Free PMC article.
-
The secreted neuronal signal Spock1 promotes blood-brain barrier development.Dev Cell. 2023 Sep 11;58(17):1534-1547.e6. doi: 10.1016/j.devcel.2023.06.005. Epub 2023 Jul 11. Dev Cell. 2023. PMID: 37437574
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous